Please turn JavaScript on
Stockmark.IT icon

Stockmark.IT

Subscribe to Stockmark.IT’s news feed.

Click on “Follow” and decide if you want to get news from Stockmark.IT via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to Stockmark.IT comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from Stockmark.IT which you are really interested in. Click on the blue “Filter” button below to get started.

Title: Stockmark.IT

Publisher:  categoryx
Message frequency:  10 / day

Message History

In a surprising turn of events, the low-cost airline EasyJet has become the target of a hostile takeover attempt by Castlelake, an American investment fund. With a bid valued at £4.7 billion, Castlelake’s aggressive approach marks a significant escalation in its months-long overture towards the airline, which has previously turned away three separate proposals. The […]

Read full story
The fate of TG Jones, the high street retailer formerly known as the high street arm of WH Smith, hangs precariously in the balance as the company embarks on a critical restructuring plan aimed at averting imminent collapse. The stakes are high, with the potential closure of up to 150 of its 450 stores and […]

Read full story
In a landscape marked by economic uncertainty and political turmoil, one might expect a significant retreat from the once golden allure of London property. However, the opposite has unfolded. The city continues to thrive as a nexus for international investment, drawing billionaires and multimillionaires alike who are keen to secure their wealth in one of […]

Read full story
The Magnum Ice Cream Company has recently found itself at the epicentre of both financial scrutiny and social contention since its spin-off from Unilever. Dubbed the most shorted stock in continental Europe, Magnum’s issues reflect not merely its corporate manoeuvring but also deeper societal undercurrents that may shape its future. The challenges it faces are […]

Read full story
The recent resumption of negotiations between AstraZeneca and NHS England concerning the availability of the breast cancer drug Enhertu marks a potentially significant turning point for patients suffering from incurable forms of the disease. After a protracted breakdown in discussions, this renewed dialogue has sparked optimism that this innovative treatment might finally be acc...

Read full story